

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Confirmation No. 5560

Hasegawa et al.

Application No. 10/567,766

Filed: February 10, 2006

For: NOVEL VACCINE CONTAINING ADJUVANT
CAPABLE OF INDUCING MUCOSAL IMMUNITY

STATEMENT REGARDING SEQUENCE LISTING


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sirs:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed October 27, 2006, a copy of which is attached, Applicants have reviewed the subject application in its entirety and do not believe that the application contains a disclosure of nucleotide and/or amino acid sequences requiring the submission of a sequence listing in accordance with 37 CFR 1.821(c). Therefore, Applicants are not submitting a written and a computer-readable sequence listing.

If, in the opinion of the Office, the application requires a sequence listing, the Office is invited to contact the undersigned attorney.

Respectfully submitted,



Date: December 29, 2006

Carol Larcher, Reg. No. 35,243
BARNES & THORNBURG LLP
P.O. Box 2786
Chicago, Illinois 60690-2786
(312) 357-1313 (telephone)
(312) 759-5646 (facsimile)
Customer No. 23644